{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:29:25Z","timestamp":1771518565581,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jconrel.2022.12.021","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T18:31:33Z","timestamp":1671647493000},"page":"988-1001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Delineating the tumour microenvironment response to a lipid nanoparticle formulation"],"prefix":"10.1016","volume":"353","author":[{"given":"Jessica","family":"Ngai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Presley","family":"MacMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R.","family":"Kingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary P.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren C.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.12.021_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng Transl Med."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0010","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0015","doi-asserted-by":"crossref","first-page":"14080","DOI":"10.1021\/acsnano.1c04510","article-title":"Specific endothelial cells govern nanoparticle entry into solid tumors","volume":"15","author":"Kingston","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0020","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.1c11578","article-title":"Macrophages actively transport nanoparticles in tumors after extravasation","author":"Lin","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2009.05.036","article-title":"Liposome drugs\u2019 loading efficiency: A working model based on loading conditions and drug\u2019s physicochemical properties","volume":"139","author":"Zucker","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0035","first-page":"22","article-title":"Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes","volume":"16","author":"Rahman","year":"1986","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0040","series-title":"Pharmacological, Toxicological, and Therapeutic Evaluation in Mice of Doxorubicin Entrapped in Cardiolipin Liposomes","article-title":"Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes - PubMed","author":"Rahman","year":"1985"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1061186021000072447","article-title":"Dose dependency of pharmacokinetics and therapeutic efficacy of Pegylated liposomal doxorubicin (DOXIL) in murine models","volume":"10","author":"Gabizon","year":"2008","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0050","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jnci\/81.19.1484","article-title":"Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times","volume":"81","author":"Gabizon","year":"1989","journal-title":"Jnci J National Cancer Inst"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0055","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1018907715905","article-title":"Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-Derivatized phospholipid: pharmacokinetic studies in rodents and dogs","volume":"10","author":"Gabizon","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0065","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","article-title":"The dose threshold for nanoparticle tumour delivery","volume":"19","author":"Ouyang","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0070","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.103.053413","article-title":"Multiple injections of Pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity","volume":"306","author":"Charrois","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0075","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3109\/08982109409037065","article-title":"Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth\u00ae liposomes (Doxil\u00ae)","volume":"4","author":"Working","year":"2008","journal-title":"J Liposome Res"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0080","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0085","doi-asserted-by":"crossref","first-page":"eaay1601","DOI":"10.1126\/sciadv.aay1601","article-title":"Nanoparticle interactions with immune cells dominate tumor retention and induce T cell\u2013mediated tumor suppression in models of breast cancer","volume":"6","author":"Korangath","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","article-title":"Systemic dysfunction and plasticity of the immune macroenvironment in cancer models","volume":"26","author":"Allen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexmp.2006.06.007","article-title":"Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: Association with tumor-derived growth factors","volume":"82","author":"Dupre","year":"2007","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2613.2007.00539.x","article-title":"The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci","volume":"88","author":"DuPre","year":"2007","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0105","first-page":"752","article-title":"Preclinical Expert Report","volume":"15","author":"Working & Dayan","year":"1996","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2009.12.002","article-title":"Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance","volume":"143","author":"de Smet","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0115","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1038\/ncomms9692","article-title":"Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug","volume":"6","author":"Miller","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0120","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.1021\/acsnano.8b03900","article-title":"Quantifying the ligand-coated nanoparticle delivery to Cancer cells in solid tumors","volume":"12","author":"Dai","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0125","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: A randomized phase III study of Pegylated liposomal doxorubicin versus Topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0130","first-page":"1097","article-title":"Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy","volume":"6","author":"Ellerhorst","year":"1999","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0959-8049(01)00329-X","article-title":"Caelyx\u00ae phase II studies in ovarian cancer","volume":"37","author":"Johnston","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1081\/CNV-120016412","article-title":"Phase II trial of Pegylated-liposomal doxorubicin (DoxilTM) in sarcoma*","volume":"21","author":"Skubitz","year":"2003","journal-title":"Cancer Investig."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0145","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1189\/jlb.1107762","article-title":"Macrophages define the invasive microenvironment in breast cancer","volume":"84","author":"Pollard","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0155","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/JTO.0b013e3181eba692","article-title":"Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma","volume":"5","author":"Ohtaki","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0160","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.553967","article-title":"Tumor-associated neutrophils and macrophages\u2014Heterogenous but not chaotic","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0170","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1073\/pnas.1907646116","article-title":"Assessing micrometastases as a target for nanoparticles using 3D microscopy and machine learning","volume":"116","author":"Kingston","year":"2019","journal-title":"Proc National Acad Sci"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0175","doi-asserted-by":"crossref","first-page":"2201043","DOI":"10.1002\/adma.202201043","article-title":"PET-CT imaging of polymeric nanoparticle tumor accumulation in patients","volume":"34","author":"Miedema","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0180","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0185","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-12-3518","article-title":"Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake","volume":"73","author":"Arjaans","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.131848","article-title":"Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response","volume":"16","author":"Dobosz","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.12.021_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100924","article-title":"Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression","volume":"35","author":"Chen","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2022.12.021_bb0205","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with Cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia New York N Y"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922008355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922008355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:44:01Z","timestamp":1759164241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922008355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"alternative-id":["S0168365922008355"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.021","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delineating the tumour microenvironment response to a lipid nanoparticle formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}